<code id='5F4047DF4A'></code><style id='5F4047DF4A'></style>
    • <acronym id='5F4047DF4A'></acronym>
      <center id='5F4047DF4A'><center id='5F4047DF4A'><tfoot id='5F4047DF4A'></tfoot></center><abbr id='5F4047DF4A'><dir id='5F4047DF4A'><tfoot id='5F4047DF4A'></tfoot><noframes id='5F4047DF4A'>

    • <optgroup id='5F4047DF4A'><strike id='5F4047DF4A'><sup id='5F4047DF4A'></sup></strike><code id='5F4047DF4A'></code></optgroup>
        1. <b id='5F4047DF4A'><label id='5F4047DF4A'><select id='5F4047DF4A'><dt id='5F4047DF4A'><span id='5F4047DF4A'></span></dt></select></label></b><u id='5F4047DF4A'></u>
          <i id='5F4047DF4A'><strike id='5F4047DF4A'><tt id='5F4047DF4A'><pre id='5F4047DF4A'></pre></tt></strike></i>

          
          WSS
          Stock exchange
          Drew Angerer/Getty Images

          Sage Therapeutics said Monday that it may need to reduce costs, including through employee layoffs, following the Food and Drug Administration’s denial of its rapid-acting drug for major depressive disorder.

          On Friday, the agency granted market clearance for the drug, called Zurzuvae, to treat women with postpartum depression, a smaller commercial market. Sage failed to convince regulators to also approve the drug for depression, a broader condition.

          advertisement

          “We don’t agree with the FDA review,” Sage CEO Barry Greene said during an earnings call, a point he made repeatedly. “We are evaluating the [FDA’s response letter] and as soon as we can provide more clarity, we will, on what the next steps are.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          comprehensive